Cover

Polycystic Ovary Syndrome

Novel Insights into Causes and Therapy

Editor(s): Macut D. (Belgrade) 
Pfeifer M. (Ljubljana) 
Yildiz B.O. (Ankara) 
Diamanti-Kandarakis E. (Athens) 
Table of Contents
Vol. 40, 2013
Section title: Paper

Obesity, Adipokines and Metabolic Syndrome in Polycystic Ovary Syndrome

Carmina E.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The complex mechanisms linking fat excess to metabolic syndrome are not well understood, but several experimental studies have shown that altered production of adipokines plays a main role in development and progression of this disorder. In particular, reduced secretion of adiponectin has a crucial role in inducing insulin resistance but also in determining the clustering of elevated triglycerides and small, dense LDL particles. Increased leptin secretion may be responsible for sympathetic nervous system overactivity and hypertension, while reduced omentin may have an important permissive role in the development of atherogenic processes. Finally, cytokines and other adipokines (resistin, visfatin) determine and modulate the inflammatory process that is an essential component of this condition of cardiovascular risk. Because obesity is prevalent in polycystic ovary syndrome (PCOS), it is not surprising that patients with PCOS present altered adipokine levels and increased prevalence of metabolic syndrome. However, because of the presence of other CV risk factors (androgen excess), in PCOS adipokine dysfunction is particularly severe. Understanding and treating adipokine dysfunction in young women with PCOS is an essential component of any politics of prevention of CV diseases in the general population.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Carmina E: Metabolic syndrome in polycystic ovary syndrome. Min Ginecol 2006;58:109-114
  2. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Di Fede G, Rini GB: Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92:2500-2505
  3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935
  4. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA: Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006;154:141-145
  5. Rizzo M, Longo RA, Guastella E, Rini GB, Carmina E: Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. J Endocrinol Invest 2011;34:422-426
  6. Halberg N, Wernstedt-Asterholm I, Scherer PE: The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008;37:753-768
  7. Gautron L, Elmquist JK: Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011;121:2087-2093
  8. Enriori PJ, Sinnayah P, Simonds SE, Garcia Rudaz C, Cowley MA: Leptin action in the dorsomedial hypothalamus increases sympathetic tone to brown adipose tissue in spite of systemic leptin resistance. J Neurosci 2011;31:12189-12197
  9. Guerre-Millo M: Adiponectin: an update. Diabetes Metab 2008;34:12-18
  10. Carmina E, Chu MC, Moran C, Tortoriello D, Vardhana P, Tena G, Preciado R, Lobo R: Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril 2008;89:642-648
  11. Matsuzawa Y: Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010;16:1896-1901
  12. Cook JR, Semple RK: Hypoadiponectinemia – cause or consequence of human ‘insulin resistance’?. J Clin Endocrinol Metab 2010;95:1544-1554
  13. Weiss R, Otvos JD, Flyvbjerg A, Miserez AR, Frystyk J, Sinnreich R, Kark JD: Adiponectin and lipoprotein particle size. Diabetes Care 2009;32:1317-1319
  14. Schwartz DR, Lazar MA: Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011;22:259-265
  15. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-747
  16. Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS: Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf) 2011;75:628-635
  17. Kim SM, Cho GJ, Yannakoulia M, Hwang TG, Kim IH, Park EK, Mantzoros CS: Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism 2011;60:1294-1299
  18. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y: Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011;408:339-343
  19. Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, Zhao LY: Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011;16:657-662
  20. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH: Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011;22:103
  21. Ernst MC, Sinal CJ: Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010;21:660-667
  22. Feng X, Li P, Zhou C, Jia X, Kang J: Elevated levels of serum chemerin in patients with obstructive sleep apnea syndrome. Biomarkers 2012;17:248-253
  23. Conroy R, Espinal Y, Fennoy I, Accacha S, Boucher-Berry C, Carey DE, Close S, DeSantis D, Gupta R, Hassoun AA, Iazzetti L, Jacques FJ, Jean AM, Michel L, Pavlovich K, Rapaports R, Rosenfeld W, Shamoon E, Shelov S, Speiser PW, Ten S, Rosenbaum M: Retinol binding protein 4 is associated with adiposity-related co-morbidity risk factors in children. J Pediatr Endocrinol Metab 2011;24:913-919
  24. Lumeng CN, Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest 2011;121:2111-2117
  25. Samaan MC: The macrophage at the intersection of immunity and metabolism in obesity. Diabetol Metab Syndr 2011;3:29
  26. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G, Lobo RA: Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005;152:389-394
  27. Sathyapalan T, Atkin SL: Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010;2010:758656
  28. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA: Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril 2009;91:1332-1335
  29. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, Randeva HS: Omentin-1, a novel adipokine, is decreased in overweight insulinresistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008;57:801-808
  30. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS: Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006;91:5022-5028
  31. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS: Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501-1507
  32. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, Lewandowski KC, O'Hare JP, Lehnert H, Randeva HS: Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971-1977
  33. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS: Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005;280:18073-18080
  34. Gonzalez F: Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012;77:300-305


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00